SEATTLE--(BUSINESS WIRE)--ZymoGenetics, Inc. (NASDAQ:ZGEN) today reported improved financial results for the third quarter ended September 30, 2009. The company’s net loss for the quarter declined substantially to $11.4 million, or $0.17 per share, from $28.8 million, or $0.42 per share, for the third quarter of 2008. Revenues for the third quarter of 2009 increased by 131% compared to the third quarter of 2008 as a result of increased sales of RECOTHROM® Thrombin, topical (Recombinant) and higher collaboration and license revenues. Expenses for the third quarter of 2009 decreased by 20% from the third quarter of 2008 largely as a result of the company’s cost reduction efforts.
